SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Food - Beverages >

MusclePharm Corporation (MSLP)

MSLP RSS Feed
Add MSLP Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/23/2017 2:50:30 PM - Followers: 376 - Board type: Free - Posts Today: 2






4721 Ironton Street
Building A
Denver, CO 80239
Website: http://www.musclepharm.com
Twitter: https://twitter.com/#!/MusclePharm
Facebook: http://www.facebook.com/MusclePharm
Phone: 303-396-6100
Email: info@musclepharm.com
 

Investor Kit: http://www.qualitystocks.net/content/clients/mslp-summary.pdf
 

MusclePharm News and Updates
 

(OTC QB: MSLP) MusclePharm: Money Report Interview of CEO Brad Pyatt (Fox Business)

See Dave Gentry's interview of CEO Brad Pyatt's on "The RedChip Money Report."

MusclePharm Muscling in On the Big Boys - A MUST Read About MusclePharm's 2013 Projections


Reuters.com: MusclePharm Corp Completes $12 Million Offering of Series D Convertible Stock


MusclePharm Corp announced that it has successfully completed the final closing of a $12.0 million registered direct offering of its Series D Convertible Preferred Stock. The Frost Group, LLC, headed by Miami entrepreneur Dr. Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million dollars. MusclePharm issued a total of 1,500,000 shares of its Series D Convertible Preferred Stock in a registered direct offering at a price of $8.00 per share. Each share of Series D Convertible Preferred Stock is convertible into two shares of common stock, subject to adjustment. The net proceeds to MusclePharm from the closings were approximately $10.8 million after deducting placement agent fees and offering expenses. GVC Capital LLC acted as the lead placement agent for this offering.

MusclePharm's CEO Letter to Shareholders Carried by NBC

Forbes Magazine: Billionaire Pharmaceutical Entrepreneur Makes Bet On Fast Growing Supplement Manufacturer: MusclePharm

SeekingAlpha.com: Some Thoughts On MusclePharm CEO's Letter To Shareholders

Yahoo! Finance: Manager of Royce Funds to Appear on This Week's "The RedChip Money Report"


Announcement of CEO Brad Pyatt's appearance is also made in this press release.

MusclePharm CEO Issues Letter to Shareholders

DENVER, CO, Feb 15, 2013 (MARKETWIRE via COMTEX) -- MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, is pleased to announce that it has released a letter from its CEO, Bradley J. Pyatt, to update shareholders on the current status of the Company.

Dear Valued MusclePharm Shareholders,

I want to personally thank you for being a MusclePharm Corporation shareholder. We are excited about the future of our Company and this letter outlines our vision and plans for the future.

Over the past three years we achieved exponential product sales growth, growing from around $1.4 million in revenue for 2009, to approximately $78 million in 2012. However, to finance that growth from essentially a startup mode we had to utilize dilutive financing instruments, which were very expensive and hurt our financial performance, and as one would expect, our stock price suffered too. All of us at MusclePharm believe that our market capitalization today is not a valid reflection of our Company's current underlying fundamentals. Below I address how we are proactively addressing our future, which we believe should result in better financial results and a higher stock price as we move forward.

As you probably know, we recently completed a $12.0 million registered direct offering of our Series D Convertible Preferred Stock at $8.00 per share. Each preferred share is convertible into two shares of our common stock. In 2012, we spent considerable time cleaning up the Company's balance sheet and raising other capital to support our growth. In late 2012, we issued 516,308 shares of our common stock to several accredited investors pursuant to conversions of warrants to purchase an aggregate of 728,648 shares of our common stock. As a result of these warrant conversions and other extinguishments of derivative liabilities, our stockholders' deficit decreased from approximately $11.0 million at June 30, 2012 to approximately $7.3 million at September 30, 2012 and our derivative liabilities decreased from approximately $7.9 million at June 30, 2012 to approximately $25,000 at September 30, 2012. Now, in the first quarter of 2013, after our registered direct offering, we believe we have positioned the Company to continue growing with the proper type of capital structure that will allow us to focus on profitability.

With the proceeds from our recently completed offering we paid off all our mezzanine and short-term debt. We are now debt free. We expect to use the remaining proceeds from the offering to launch new products, seek to expand internationally, and seek to increase our U.S. sales force.

As you also are probably aware, in late 2012 we completed an 850:1 reverse stock split. The reverse split was a necessary step for us to seek a listing on a stock exchange. We expect we will have such a listing this summer after we post our 2013 first quarter results. There are several benefits to being listed on a stock exchange, but the most important is the ability to seek institutional investment in our shares. The institutions that were looking at investing in our Company over the past few years declined for the most part, citing our lack of a stock exchange listing. Going forward, these investors will have the ability to participate in our Company once we are listed on an exchange.

Our Growth Story

In September of 2008, we started MusclePharm out of my garage in Denver, Colorado. Fast-forward to today and we are recognized as a global leader in a multi-billion dollar industry. Our gross revenue increased exponentially as follows*:

Dollars in millions 2009: $0 - $1 2010: $1 - 4 (300% gain YOY) 2011: $4 - 17 (325% gain YOY) 2012: $17 - 78 (370% gain YOY)

* These numbers have been rounded for ease of reading, and 2012 is unaudited.

In a time when our economy has struggled, we achieved revenue growth of approximately 300%+ year over year. We project we will increase our gross revenues in 2013 to over $100 million.

At the 2012 Bodybuilding.com Supplement Awards, we received three Awards of Excellence; we received (i) the "Brand of the Year" award, (ii) the "Packaging of the Year" award, and (iii) the "Pre-Workout Supplement of the Year" award for Assault(TM). On top of that, we've won over 15 other industry awards since our inception.

Our headquarters in Denver, Colorado has a state-of-the-art over 30,300 square feet athletic facility with a medical and clinical testing department, complete with equipment for measuring and conducting athletic clinical studies and supporting athletes. Our medical and clinical professionals consist of several nationally recognized medical doctors and nutritional experts who oversee our product research, formulation, efficacy analysis and testing. It also serves as a place for some of the world's top athletes to come and train and be educated on the latest nutritional advancements that we have under development.

Our primary growth strategy is to:

-- Increase our product distribution and sales through increased market penetrations both domestically and internationally;

-- Increase our margins by focusing on streamlining our operations and seeking operating efficiencies in all areas of our operations;

-- Continue to conduct additional testing of the safety and efficacy of our products and formulate new products; and

-- Increase awareness of our products by increasing our marketing and branding opportunities through endorsements, sponsorships and brand extensions.

Our core marketing strategy is to brand MusclePharm as the "must have" fitness brand for workout enthusiasts and elite athletes. We seek to be known as the "athlete's company," run by athletes who create their products for other athletes, both professional and otherwise. We believe that our marketing mix of endorsers, sponsorships and providing sample products for our retail resellers to use is an optimal strategy to increase sales.

In addition:

-- Our products are currently sold in over 110 countries, with the goal of reaching 175 countries in the next few years.

-- Our products are available in over 10,500 U.S. retail outlets with the goal of reaching 20,000+ in the next few years.

-- Retail stores include GNC and Vitamin Shoppe, as well as over 100 online stores, including Bodybuilding.com, Vitacost.com, GNC.com,Amazon.com, SupplementWarehouse.com, AllStarHealth.com, LuckyVitamin.com, Dick's Sporting Goods, and many more

We recently renegotiated our terms with our manufacturers and have refined our distribution model, and as a result, we should experience better sales margins. On top of this, we have reviewed our operating costs and are cutting several non- essential expenses. We also recently launched a new product called Amino1. To date, it is the fastest growing product (sku) we have ever had here at MusclePharm.

Finally, in mid 2012, we hired an experienced CFO, Gary Davis, who most recently served as executive vice president and CFO for Bodybuilding.com for almost six years. Bodybuilding.com is a world leader in sports fitness and nutritional supplements and is a very large website for nutritional products. Gary's experience includes extensive experience as a chief financial officer with strengths in external and management reporting and analysis, accounting, tax, treasury, human resources and risk management functions in public and private companies along with the dietary supplement industry. He provides strength and direction for the demands and growth of MusclePharm.

Going from no revenues to over $78 million in less than four years was impressive growth, but all of us here at MusclePharm have the goal of reaching $500 million in annual sales -- but only at a profitable level. We are excited about focusing on our core business without the after effects of burdensome financings.

If you have any questions regarding our Company, please feel free to contact me directly or our office at the numbers listed below.

Sincerely,

Brad Pyatt
Chief Executive Officer


Contact:
MusclePharm Investor

Alex Partners, LLC
Scott Wilfong
President
Telephone: 425-242-0891
Email
 

Opko's Billionaire CEO Invests In MusclePharm

Read John H. Ford's thoughts on current investment strategies.

MusclePharm Reports Revenue Growth

MusclePharm Corp. (MSLP) is a healthy life-style company focused on developing and manufacturing a full line of National Science Foundation approved nutritional supplements that do not use any substances banned in the sports industry. The company continues to expand rapidly, with revenues growing from $80,739 in 2008, $1,016,000 in 2009, and $4,076,764 in 2010 to $3,517,774 for just the first quarter of 2011.

Net sales for the first three months of 2012 increased nearly four-fold to approximately $19 million, up from $4 million for Q1 2011. The company's international sales grew to approximately $4 million from $1 million in Q1 2011. There were general and administrative expenses of approximately $5 million, or 26 percent of net sales, compared with $2 million, or 50 percent of net sales for the same quarter last year. The company's income from operations increased to approximately $1 million, compared to a similar loss of $1 million for Q1 2011. Its 2012 revenues for 2012 - as of Q3 2012 - are approximately $51 million.

MusclePharm is expected to exceed previous revenues, with numbers in the $100 million for 2013 likely. Its debt levels and profit margins have had some issues, mainly because due to the company's young age and sales volumes. However, these have been eliminated and the profit margins are anticipated to turn positive. The increase in sales volumes are expected to grow with the company's lower manufacturing costs.

MusclePharm's revenues stand as follows:

o 2009 revenues: $1 million
o 2010 revenues: $4.1 million
o 2011 revenues: $17 million
o 2012 revenues: $51 million (as of the third quarter)

Current CEO Brad Pyatt founded the company to develop a superior line of nutritional supplements that would help fellow athletes improve their performance in a way that existing supplements did not. Even as the company has grown, its mission has remained the same: to improve its customers' lives, increase their ability to excel, use cutting-edge science to develop the best nutritional supplements on the market and provide a safe option for athletes.

Now sold in more than 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe locations, the company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. The products are also sold in over 100 online stores, including BodyBuilding.com, Amazon.com and Vitacost.com.

Over the last few years, the consumption of sports nutrition products has shifted to mainstream consumers who have become the key drivers of growth within the industry. According to BCC Research, the U.S. is the largest consumer market for sports nutrition products, with annual sales reaching $22 billion in 2007, and projected sales of $29 billion in 2013. With a full line of supplements and an extensive distribution network, MusclePharm is well positioned to capitalize on the growing demand.

News: http://finance.yahoo.com/q/h?s=MSLP.OB
SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=musclepharm
 

MusclePharm Reviewed: MusclePharm Seeks NASDAQ Listing, Eliminates Debt, Grows Q3 Revenues by $14M YoY

Next year will be pivotal for MusclePharm. The company is nearing the $100 million threshold of annual sales, its brand has broad acceptance in the sports community, and it has a large distribution network of major domestic and international stores. Now that the company has cleaned its balance sheet by eliminating toxic financing, shareholders will expect market capitalization to better reflect sales numbers. A possible NASDAQ listing, a recent reverse stock split that brought the company's stock price to over $4 per share, and profitability potential are all factors that will contribute to MusclePharm's pivotal 2013.

Read full review and conclusion.

Meet the Athletes Who Trust Their Careers to MusclePharm Products

Read a series of diet, nutrition, training, other articles on the MusclePharm website

Watch our workout, interview, and industry news videos


Scientifically Advanced Research Protocol

Each and every product sold by MusclePharm® is the end result of a long development process involving leading nutrition scientists doctors, and top professional athletes in the country.

Step 1: The Vision

CEO, Brad Pyatt, President and fitness icon, Cory Gregory, and top sports nutritionist, Eric Serrano, MD take the first step by envisioning a new nutritional supplement with a specific set of performance properties

Step 2: The Formulation Process

Dr. Eric Serrano, the leading sports nutrition doctor in the US, who is the company's medical director and formulator, begins putting together several scientifically advanced - often breakthrough - combinations and ratios of ingredients resulting in superior formulations.

Step 3: Athlete Protocol Test

At the world reknown MP Performance Center, preliminary formulations of new products are tested on elite professional athletes. Product samples developed at the MP Performance Center are also given to athletes and strength coaches in the NFL, MMA, MLB, and other organizations for further analysis. MusclePharm is the first to use the field as it's lab, truly combining science with athletics. At our 30,000 sq. ft. training facility we use state-of-the-art technology like Omega Wave, DEXA, and Kaiser performance equipment to gather cutting-edge feedback about our formulations. Our medical advisory team, strength coaches, and top fitness experts evaluate the results to give us a practical read on the effectiveness of our products.

Step 4: Research and Product Testing

After athlete testing, the formulation is forwarded to Dr. Jeffrey Stout, a professor of exercise physiology at the University of Oklahoma, who performs an in-depth review of ingredient ratios and combinations to ensure it is sound from both a nutritional and health standpoint. Dr. Stout oversees clinical trials so that product claims are not based solely on published data from individual ingredients but from finished goods.

Step 5: Compliance and Safety

All products are checked against internationally published lists to ensure that no banned substances are included. All production runs are conducted in a state-of-the-art facility that follows government-approved Good Manufacturing Practices (cGMP). Before being made available to the public, all products are analytically verified for purity and verified for label claim accuracy to ensure that the information we put on the label is 100% accurate. Following testing, reference samples are kept so that we can hold our products to the highest quality assurance standards.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSLP
Current Price
Volume:
Bid Ask Day's Range
MSLP News: Statement of Changes in Beneficial Ownership (4) 05/15/2017 12:36:41 PM
MSLP News: Quarterly Report (10-q) 05/12/2017 01:04:20 PM
MSLP News: Current Report Filing (8-k) 05/10/2017 04:37:14 PM
MSLP News: Amended Statement of Beneficial Ownership (sc 13d/a) 05/04/2017 02:17:22 PM
MSLP News: Amended Annual Report (10-k/a) 05/01/2017 02:07:04 PM
PostSubject
#79441   The trend over the last seven months is Dr Badman 05/23/17 02:50:30 PM
#79440   Someone heard you. I also heard the new Dr Badman 05/23/17 02:31:24 PM
#79439   And more important, no one is willing to codie 05/22/17 06:27:02 PM
#79438   No one is willing to sell for lower. Dr Badman 05/22/17 02:44:14 PM
#79437   This lame duck stock price is firmly set. avocet 05/22/17 08:01:58 AM
#79436   The lame duck price is set. avocet 05/22/17 07:55:51 AM
#79435   Ya think? Have they ever done anything without codie 05/21/17 08:57:32 PM
#79434   Was probably losing money. Dr Badman 05/18/17 08:56:29 PM
#79433   No more MMA for Musclepharm. Their fight team codie 05/18/17 12:08:26 PM
#79432   The illusion of benefit gone sour. avocet 05/18/17 10:51:07 AM
#79431   Reminds me of a worn out elastic waist band. avocet 05/16/17 11:03:26 AM
#79430   Smart. Lots of upside here. The natural series Dr Badman 05/15/17 03:50:37 PM
#79429   Amerop just purchased another 75k shares at $2.00 stupified777 05/15/17 01:18:11 PM
#79428   In my opinion : ) it will be stupified777 05/15/17 12:27:06 PM
#79423   What's the buyout price? I must've skipped that part. dareinkler 05/12/17 07:24:27 AM
#79422   Revenue down over 40%. Stock price plunges. Nothing codie 05/12/17 12:05:40 AM
#79421   I'm buying today lol. Loss this quarter down Dr Badman 05/11/17 02:54:00 PM
#79420   Looks like the market loved the mediocre, "flat" stupified777 05/11/17 12:51:20 PM
#79419   Nothing exciting at all...not sure what I expected. stupified777 05/11/17 09:37:59 AM
#79418   Wonderful. Can't wait to read the transcript. bajista 05/11/17 07:44:43 AM
#79417   As did the conference call...can I go on stupified777 05/11/17 12:07:38 AM
#79416   A less miserable quarter but it still sucked. bajista 05/10/17 11:43:34 PM
#79415   Go Mslp$$$$$$$$$ johncon 05/10/17 01:53:17 PM
#79414   Big day for me tomorrow. Hopefully they tell stupified777 05/09/17 03:14:58 PM
#79413   MusclePharm Appoints Daniel Clark as UK Sales Director bajista 05/09/17 01:59:05 AM
#79412   I saw some FitMiss product in the clearance bajista 05/08/17 04:19:22 PM
#79411   Any guesses on financials for the Qtr? I stupified777 05/08/17 02:41:30 PM
#79410   That's what I've been hoping for awhile. Let's Neuronal 05/05/17 05:57:34 PM
#79409   So between Drexler and Amerop (Drexlers buddy) they stupified777 05/05/17 02:59:03 PM
#79408   Fits his history w his fathers company and Dr Badman 05/05/17 01:50:43 PM
#79407   That's exactly what I'm hoping to God for! Lol stupified777 05/05/17 01:27:02 PM
#79406   Seeing as he wrote a bonus for selling bajista 05/05/17 12:50:56 PM
#79405   My gut tells me we see buyout news stupified777 05/04/17 02:57:00 PM
#79404   I think so as well. stupified777 05/03/17 01:49:57 PM
#79403   Positive trend. Dr Badman 05/03/17 01:47:34 PM
#79402   Haven't heard on the new line although I stupified777 05/03/17 01:37:49 PM
#79401   Next weds earnings release after bell with cc. stupified777 05/03/17 01:36:54 PM
#79400   Yes. When? Do you know when natural Dr Badman 05/03/17 11:48:00 AM
#79399   First conference call in many many qtrs. Is stupified777 05/03/17 10:36:39 AM
#79398   Probably pretty cheap endorsement deal. Good bang for Dr Badman 04/19/17 10:31:04 AM
#79397   Again, I'm not sure what this is costing Hunterdog 04/19/17 09:25:40 AM
#79396   What is this? Drexler is even crazier than bajista 04/18/17 11:50:49 AM
#79395   Only 550% more to go! Go MSLP! dareinkler 04/12/17 08:31:58 PM
#79394   Yes and also left out the fact that stupified777 04/12/17 06:48:32 PM
#79393   You left out the part where the stock codie 04/12/17 06:26:58 PM
#79392   His leadership responsibilities were removed and the company stupified777 04/12/17 06:07:24 PM
#79391   What happened shortly after Pyatt bought in at dareinkler 04/12/17 05:20:55 PM
#79390   Insider Trading Activity MusclePharm Corp (OTCMKTS:MSLP) – Major Hunterdog 04/12/17 10:06:55 AM
#79389   Insider Buys? Hunterdog 04/12/17 10:05:07 AM
#79388   Great opportunity to average down in you are nomoneyleft 04/06/17 05:18:30 PM
PostSubject